Intelligence Platform

Patents

Browse 650 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

US 10683277

Triazole derivatives as P2Y14 receptor antagonists

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10676469

Kappa opioid receptor antagonists and products and methods related thereto

BLACKTHORN THERAPEUTICS, INC. · Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10653743

Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonis

Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10654842

Dopamine D3 receptor antagonist compounds

Indivior UK Limited · Granted Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10626146

α4β7 thioether peptide dimer antagonists

Protagonist Therapeutics, Inc. · Granted Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10624850

Emulsion formulations of an NK-1 receptor antagonist and uses thereof

Heron Therapeutics, Inc. · Granted Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10617673

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders,

Jenrin Discovery, LLC · Granted Tue Apr 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10610534

Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat ad

Corcept Therapeutics Incorporated · Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10604507

Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

CRINETICS PHARMACEUTICALS, INC. · Granted Tue Mar 31 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10597448

Methods for treating visceral pain associated with interstitial cystitis by administering

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Mar 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10590107

Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agon

Theravance Respiratory Company, LLC · Granted Tue Mar 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10577361

Dopamine D3 receptor antagonists having a morpholine moiety

Indivior UK Limited · Granted Tue Mar 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10570092

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance Biopharma R&D IP, LLC · Granted Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10562884

Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

CRINETICS PHARMACEUTICALS, INC. · Granted Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10556945

Antagonist antibodies directed against calcitonin gene-related peptide and methods using s

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Feb 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10544188

Inhibitor of apoptosis protein (IAP) antagonists

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10538530

Vasopressin receptor antagonists and products and methods related thereto

BLACKTHORN THERAPEUTICS, INC. · Granted Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10532096

Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10508103

Benzimidazole-linked indole compound acting as novel divalent IAP antagonist

Medshine Discovery Inc. · Granted Tue Dec 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10464992

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10456380

Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antag

Cumberland Pharmaceuticals Inc. · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10407468

Methods for synthesizing α4β7 peptide antagonists

Protagonist Therapeutics, Inc. · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10406226

Method of manufacturing VEGF antagonist fusion proteins

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10407443

5-HT3 receptor antagonists

Takeda Pharmaceutical Company Limited · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)